Re-Examination Of Amgen, BMS Filings Highlights Difference Between EU And US Regulators

 
• By Vibha Sharma

Unlike in the US, the European Medicines Agency does not usually recommend approval of drugs based on early-phase trials.

Reconsider
The EMA Is Re-Examining Filings From Amgen And BMS • Source: Shutterstock

More from Clinical Trials

More from R&D